1. Japan Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
SanBio Company Limited

SanBio Company Limited

SNBIF
SanBio Company LimitedUS flagOther OTC
16.45
USD
- -
- -
1.28BMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
5.34
82.41
26.94
21.15
10.81
15.28
8.75
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-15.41
44.31
-22.67
-40.88
-86.85
-60.17
-100.91
-65.38
-90.33
-95.99
-40.48
-40.48
- -
-31.7
Free Cash Flow per Basic Share
-3.18
-5.66
-32.62
-42.18
-42.74
-81.89
-113.95
-103.4
-127.49
-128.49
-73.8
-50.66
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-149.67
-99.56
-26.88
-65.99
-151.63
-87.42
-18.26
-34.67
-96.2
-30.56
20.92
25.24
- -
34.69
Tangible Book Value per Share
-51.32
-2.23
146.02
102.19
18.69
183.5
213.57
160.21
38.02
76.45
42.07
24.14
- -
22.37
Basic Weighted Avg Shares
38
39
44
45
45
49
51
52
52
58
65
71
- -
68
Sales/Revenue/Turnover
204
3,229
1,175
950
491
742
447
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
-285.99
69.64
-95.79
-203.49
-892.62
-503.49
-1,226.69
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
4
6
14
27
54
37
40
74
132
25
15
9
8
- -
Net Income, GAAP
-589
1,736
-988
-1,835
-3,940
-2,921
-5,158
-3,386
-4,678
-5,560
-2,644
-2,883
-3,843
-2,166
Effective Tax Rate (%)
- -
22.08
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
440.59
Profit Margin (%)
-288.54
53.77
-84.14
-193.28
-803.31
-393.81
-1,153.27
- -
- -
- -
- -
- -
- -
- -
Working Capital
-1,984
878
6,772
5,577
2,970
11,992
13,451
10,663
3,888
5,877
4,032
2,604
14,955
2,790
LT Debt
- -
1,100
300
1,150
2,233
4,000
3,500
2,525
2,012
665
397
129
1,110
263
Total Equity
-1,963
-87
6,367
4,595
853
8,909
10,930
8,350
2,035
4,429
2,792
1,763
13,605
1,572
Return on Invested Capital (%)
- -
-523.67
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-41.32
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-848.06
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-182.24
-83.75
-121.77

Capital Structure

FRC

•

in mil. unless spec.
Jan'24
Apr'25
Jul'25
ST Debt
268
268
268
LT Borrowings
397
330
263
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
68
69
69
Market Capitalization
38,015
41,517
39,438

Working Capital

FRC

•

in mil. unless spec.
Jan'24
Apr'25
Jul'25
Total Current Assets
4,937
4,298
3,439
Cash, Cash Equivalents & STI
4,455
3,958
3,082
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
906
503
649
Payables & Accruals
- -
- -
- -
ST Debt
268
268
268
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
147.38%
127.98%
671.71%
Free Cash Flow
15.98%
-3.84%
5.15%
Net Income, GAAP
26.36%
9.38%
33.29%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-9.68
- -
- -
- -
-40.48
2025
-2.12
- -
- -
- -
-40.48
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Keita Mori
Full Time Employees
29
Sector
Healthcare
Industry
Biotechnology
Address
St. Luke Tower Tokyo Japan 104-0044
IPO Date
Oct 12, 2015
Website
sanbio.jp
Similar Companies
NanoSphere Health Sciences Inc. (NSHSF)
NovaBay Pharmaceuticals, Inc. (NBY)
Advicenne S.A. (ADVIC.PA)
Celcuity Inc. (CELC)
Biora Therapeutics, Inc. (PROG)
TME Pharma N.V. (ALTME.PA)
Business
SanBio Company Limited (TSE:4592; OTC:SNBIF), a biopharmaceutical company founded in 2001 and headquartered in Tokyo, Japan, with additional facilities in Oakland, California, USA, researches, develops, manufactures, and commercializes regenerative cell therapies using allogeneic mesenchymal stem cells to restore neurological function damaged by disease or injury; its lead product, AKUUGO (vandefitemcel, previously SB623), is a suspension for intracranial implantation targeting chronic traumatic brain injury, ischemic stroke, and Parkinson's disease, while its pipeline also encompasses therapies for eye diseases and other central nervous system disorders through partnerships such as joint development with OcuMension (Hong Kong) Limited and collaboration with D&P Bioinnovations, Inc. for regenerative esophageal implants. The company operates primarily in Japan and the United States, advancing clinical programs with regulatory milestones including conditional approval of AKUUGO by Japan's Ministry of Health, Labour and Welfare in 2024, subsequent partial change applications for manufacturing and marketing in 2025, and an agreement with the U.S. FDA on Phase 3 trial design for traumatic brain injury. Recent developments feature secured commitment lines totaling ¥3 billion from Resona Bank, Mizuho Bank, and Mitsubishi UFJ Financial Group in 2025 for financial stability; a planned international offering to raise up to ¥14.9 billion to fund product launches and clinical trials; revision of expected approval timelines for AKUUGO partial changes; and strategic expansions including interactions for stroke indications in Japan and U.S. market entry, alongside CEO Keita Mori's appointment as Chairman of the Samurai Biotech Association in May 2025.

Company News

APIChat

  • seekingalpha.com

    SanBio Company Limited (SNBOY) Q4 2026 Earnings Call Prepared Remarks Transcript